A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Conditions

Phase I

Phase I-II

What is the purpose of this trial?

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

  • Trial with
    NextCure, Inc.
  • Start Date
    05/06/2019
  • End Date
    08/31/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Priscilla Stéve

  • Last Updated
    06/18/2019
  • Study HIC
    #2000023979